Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Receivables (2016 - 2025)

Immucell's Receivables history spans 16 years, with the latest figure at $3.5 million for Q4 2025.

  • For Q4 2025, Receivables fell 9.48% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $3.5 million, down 9.48%, while the annual FY2025 figure was $3.5 million, 9.48% down from the prior year.
  • Receivables reached $3.5 million in Q4 2025 per ICCC's latest filing, up from $2.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $7.5 million in Q3 2021 to a low of $1.5 million in Q2 2023.
  • Average Receivables over 5 years is $3.4 million, with a median of $2.6 million recorded in 2022.
  • Peak YoY movement for Receivables: surged 615.25% in 2021, then tumbled 76.93% in 2022.
  • A 5-year view of Receivables shows it stood at $2.7 million in 2021, then plummeted by 34.51% to $1.8 million in 2022, then increased by 23.56% to $2.2 million in 2023, then skyrocketed by 71.3% to $3.8 million in 2024, then decreased by 9.48% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Receivables are $3.5 million (Q4 2025), $2.6 million (Q3 2025), and $2.4 million (Q2 2025).